TDP-43 or FUS-induced misfolded human wild-type SOD1 can propagate intercellularly in a prion-like fashion

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Pokrishevsky, Edward ^a   Grad, Leslie I ^a   Cashman, Neil R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CONDITIONED MEDIUM; COPPER ZINC SUPEROXIDE DISMUTASE; DNA BINDING PROTEIN; FUS PROTEIN, HUMAN; MUTANT PROTEIN; PRION; RNA BINDING PROTEIN FUS; SMALL INTERFERING RNA; SOD1 PROTEIN, HUMAN; TDP-43 PROTEIN, HUMAN;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL; ANTIBODY SPECIFICITY; CHEMISTRY; CONDITIONED MEDIUM; GENE SILENCING; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; METABOLISM; MOTONEURON; MOUSE; PATHOLOGY; PRION; PROTEIN FOLDING; TRANSGENIC MOUSE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIBODY SPECIFICITY; CULTURE MEDIA, CONDITIONED; DNA-BINDING PROTEINS; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUTANT PROTEINS; PRIONS; PROTEIN FOLDING; RNA, SMALL INTERFERING; RNA-BINDING PROTEIN FUS; SUPEROXIDE DISMUTASE-1;

EID: 84959460659     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22155     Document Type: Article

References (53)

1. Bunton-Stasyshyn, R. K., Saccon, R. A., Fratta, P. & Fisher, E. M. SOD1 Function and Its Implications for Amyotrophic Lateral Sclerosis Pathology: New and Renascent Themes. The Neuroscientist: a review journal bringing neurobiology, neurology and psychiatry (2014).
2. Banci, L. et al. Structural and dynamic aspects related to oligomerization of apo SOD1 and its mutants. Proceedings of the National Academy of Sciences of the United States of America 106, 6980-6985 (2009).
3. Forsberg, K. et al. Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PloS one 5, e11552 (2010).
4. Pokrishevsky, E., Grad, L. I., Yousefi, M., Wang, J., Mackenzie, I. R. & Cashman, N. R. Aberrant localization of FUS and TDP43 is associated with misfolding of SOD1 in amyotrophic lateral sclerosis. PloS one 7, e35050 (2012).
5. Bosco, D. A. et al. Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nature neuroscience 13, 1396-1403 (2010).
6. Liu, H. N. et al. Lack of evidence of monomer/misfolded superoxide dismutase-1 in sporadic amyotrophic lateral sclerosis. Annals of neurology 66, 75-80 (2009).
7. Kerman, A. et al. Amyotrophic lateral sclerosis is a non-amyloid disease in which extensive misfolding of SOD1 is unique to the familial form. Acta neuropathologica 119, 335-344 (2010).
8. Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochemical and biophysical research communications 351, 602-611 (2006).
9. Neumann, M. et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 314, 130-133 (2006).
10. Kwiatkowski, T. J. Jr. et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 323, 1205-1208 (2009).
11. Vance, C. et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 323, 1208-1211 (2009).
12. Renton, A. E., Chio, A. & Traynor, B. J. State of play in amyotrophic lateral sclerosis genetics. Nature neuroscience 17, 17-23 (2014).
13. Deng, H. X. et al. FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 familial amyotrophic lateral sclerosis. Annals of neurology 67, 739-748 (2010).
14. Mackenzie, I. R. et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of neurology 61, 427-434 (2007).
15. Ravits, J. M. & La Spada, A. R. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology 73, 805-811 (2009).
16. Sekiguchi, T. et al. Spreading of amyotrophic lateral sclerosis lesions-multifocal hits and local propagation? J Neurol Neurosurg Psychiatry 85, 85-91 (2014).
17. Nonaka, T. et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell reports 4, 124-134 (2013).
18. Grad, L. I. et al. Intermolecular transmission of superoxide dismutase 1 misfolding in living cells. Proceedings of the National Academy of Sciences of the United States of America 108, 16398-16403 (2011).
19. Grad, L. I. et al. Intercellular propagated misfolding of wild-type Cu/Zn superoxide dismutase occurs via exosome-dependent and-independent mechanisms. Proceedings of the National Academy of Sciences of the United States of America 111, 3620-3625 (2014).
20. Grad, L. I., Pokrishevsky, E., Silverman, J. M. & Cashman, N. R. Exosome-dependent and independent mechanisms are involved in prion-like transmission of propagated Cu/Zn superoxide dismutase misfolding. Prion 8, 331-335 (2014).
21. Ayers, J. I. et al. Experimental transmissibility of mutant SOD1 motor neuron disease. Acta neuropathologica 128, 791-803 (2014).
22. Munch, C., O'Brien, J. & Bertolotti, A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proceedings of the National Academy of Sciences of the United States of America 108, 3548-3553 (2011).
23. Ilieva, H., Polymenidou, M. & Cleveland, D. W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. The Journal of cell biology 187, 761-772 (2009).
24. Bruns, C. K. & Kopito, R. R. Impaired post-translational folding of familial ALS-linked Cu, Zn superoxide dismutase mutants. The EMBO journal 26, 855-866 (2007).
25. Guo, J. L. & Lee, V. M. Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases. Nature medicine 20, 130-138 (2014).
26. Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51 (2013).
27. Guest, W. C., Silverman, J. M., Pokrishevsky, E., O'Neill, M. A., Grad, L. I. & Cashman, N. R. Generalization of the prion hypothesis to other neurodegenerative diseases: an imperfect fit. J Toxicol Environ Health A 74, 1433-1459 (2011).
28. Prusiner, S. B. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336, 1511-1513 (2012).
29. Deng, J. et al. FUS Interacts with HSP60 to Promote Mitochondrial Damage. PLoS genetics 11, e1005357 (2015).
30. Wang, W. et al. The ALS disease-associated mutant TDP-43 impairs mitochondrial dynamics and function in motor neurons. Human molecular genetics 22, 4706-4719 (2013).
31. Lin, M. T. & Beal, M. F. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443, 787-795 (2006).
32. Scotter, E. L. et al. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. Journal of cell science 127, 1263-1278 (2014).
33. Urushitani, M. et al. CHIP promotes proteasomal degradation of familial ALS-linked mutant SOD1 by ubiquitinating Hsp/Hsc70. Journal of neurochemistry 90, 231-244 (2004).
34. Furukawa, Y., Kaneko, K., Watanabe, S., Yamanaka, K. & Nukina, N. Intracellular seeded aggregation of mutant Cu,Zn-superoxide dismutase associated with amyotrophic lateral sclerosis. FEBS letters 587, 2500-2505 (2013).
35. Gomes, C., Keller, S., Altevogt, P. & Costa, J. Evidence for secretion of Cu,Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neurosci Lett 428, 43-46 (2007).
36. Mulcahy, L. A., Pink, R. C. & Carter, D. R. Routes and mechanisms of extracellular vesicle uptake. Journal of extracellular vesicles 3 (2014).
37. Foust, K. D. et al. Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. Molecular therapy: the journal of the American Society of Gene Therapy 21, 2148-2159 (2013).
38. Brotherton, T. E., Li, Y. & Glass, J. D. Cellular toxicity of mutant SOD1 protein is linked to an easily soluble, non-aggregated form in vitro. Neurobiology of disease 49, 49-56 (2013).
39. Murray, M. E. et al. Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta neuropathologica 122, 673-690 (2011).
40. Ritson, G. P. et al. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. The Journal of neuroscience: the official journal of the Society for Neuroscience 30, 7729-7739 (2010).
41. Tudor, E. L. et al. Amyotrophic lateral sclerosis mutant vesicle-associated membrane protein-associated protein-B transgenic mice develop TAR-DNA-binding protein-43 pathology. Neuroscience 167, 774-785 (2010).
42. Elden, A. C. et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 466, 1069-1075 (2010).
43. Brady, O. A., Meng, P., Zheng, Y., Mao, Y. & Hu, F. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. Journal of neurochemistry 116, 248-259 (2011).
44. Cassel, J. A. & Reitz, A. B. Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43. levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines. Biochimica et biophysica acta 1834, 964-971 (2013).
45. Maruyama, H. et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 465, 223-226 (2010).
46. Udan-Johns, M. et al. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. Human molecular genetics 23, 157-170 (2014).
47. Choi, J., Rees, H. D., Weintraub, S. T., Levey, A. I., Chin, L. S. & Li, L. Oxidative modifications and aggregation of Cu,Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. The Journal of biological chemistry 280, 11648-11655 (2005).
48. Hsiung, G. Y. et al. Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain: a journal of neurology 135, 709-722 (2012).
49. Hatzipetros, T. et al. C57BL/6J congenic Prp-TDP43A315T mice develop progressive neurodegeneration in the myenteric plexus of the colon without exhibiting key features of ALS. Brain research 1584, 59-72 (2014).
50. Graffmo, K. S. et al. Expression of wild-type human superoxide dismutase-1 in mice causes amyotrophic lateral sclerosis. Human molecular genetics 22, 51-60 (2013).
51. Urushitani, M., Ezzi, S. A. & Julien, J. P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proceedings of the National Academy of Sciences of the United States of America 104, 2495-2500 (2007).
52. Gros-Louis, F., Soucy, G., Lariviere, R. & Julien, J. P. Intracerebroventricular infusion of monoclonal antibody or its derived Fab fragment against misfolded forms of SOD1 mutant delays mortality in a mouse model of ALS. Journal of neurochemistry 113, 1188-1199 (2010).
53. Liu, H. N. et al. Targeting of monomer/misfolded SOD1 as a therapeutic strategy for amyotrophic lateral sclerosis. The Journal of neuroscience: the official journal of the Society for Neuroscience 32, 8791-8799 (2012).